Antibodies elicited by the 2025-2026 influenza vaccine in humans

Abstract A new H3N2 variant (named subclade K) possesses several key hemagglutinin substitutions and is circulating widely during the 2025-2026 influenza season. In this report, we completed experiments to determine if the 2025-2026 seasonal influenza vaccine elicits antibodies in humans that recognize this variant. We find that H3N2 subclade K viruses are antigenically advanced; however, the 2025-2026 seasonal influenza vaccine elicited antibodies in many individuals that efficiently recognized these viruses. Thus, the current seasonal influenza vaccine will likely be somewhat effective at preventing H3N2 subclade K virus infections.

• UD
  U.S. Department of Health and Human Services

  Award: 75N93021C00015
• NI
  National Institutes of Health

  Award: 75N93021C00015
• NI
  National Institute of Allergy and Infectious Diseases

  Award: 75N93021C00015